N,5,6-三甲基-1H-苯并咪唑-2-胺 | 107903-00-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N,5,6-三甲基-1H-苯并咪唑-2-胺
• 英文名称: N,5,6-trimethyl-1H-benzo[d]imidazol-2-amine
• 英文别名: N,5,6-trimethyl-1H-benzimidazol-2-amine
• CAS: 107903-00-4
• 化学式: C₁₀H₁₃N₃
• mdl: MFCD09909311
• 分子量: 175.233
• InChiKey: RSNYPQWOUUDLNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-3’,5’-二-叔丁-4’-羟基苯乙酮 、 N,5,6-三甲基-1H-苯并咪唑-2-胺 在 碳酸氢钠 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以38%的产率得到1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(5,6-dimethyl-2-(methylamino)-1H-benzo[d]imidazol-1-yl)ethanone
  参考文献：
  名称：

  Inhibition of Protein Kinase C-Driven Nuclear Factor-κB Activation: Synthesis, Structure−Activity Relationship, and Pharmacological Profiling of Pathway Specific Benzimidazole Probe Molecules

  摘要：

  A unique series of biologically active chemical probes that selectively inhibit NF-kappa B activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-kappa B activation.

  DOI：

  10.1021/jm1000248
• 作为产物：
  描述：

  2-bromo-5,6-dimethyl-1H-benzo[d]imidazole 、 甲胺 反应 0.5h， 以89%的产率得到N,5,6-三甲基-1H-苯并咪唑-2-胺
  参考文献：
  名称：

  Inhibition of Protein Kinase C-Driven Nuclear Factor-κB Activation: Synthesis, Structure−Activity Relationship, and Pharmacological Profiling of Pathway Specific Benzimidazole Probe Molecules

  摘要：

  A unique series of biologically active chemical probes that selectively inhibit NF-kappa B activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-kappa B activation.

  DOI：

  10.1021/jm1000248

文献信息

• Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20100152170A1

  公开（公告）日：2010-06-17

  The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.

  本发明涉及用于治疗癌症的化合物和方法。该发明提供抑制极化丝激酶的化合物，包含抑制极化丝激酶的化合物的药物组合物，并使用本发明的化合物或包含本发明化合物的药物组合物进行癌症治疗的方法。
• US8377983B2
  申请人：——

  公开号：US8377983B2

  公开（公告）日：2013-02-19
• Inhibition of Protein Kinase C-Driven Nuclear Factor-κB Activation: Synthesis, Structure−Activity Relationship, and Pharmacological Profiling of Pathway Specific Benzimidazole Probe Molecules
  作者：Satyamaheshwar Peddibhotla、Ranxin Shi、Pasha Khan、Layton H. Smith、Arianna Mangravita-Novo、Michael Vicchiarelli、Ying Su、Karl J. Okolotowicz、John R. Cashman、John C. Reed、Gregory P. Roth

  DOI：10.1021/jm1000248

  日期：2010.6.24

  A unique series of biologically active chemical probes that selectively inhibit NF-kappa B activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-kappa B activation.